Gotowa bibliografia na temat „Fibulin-2”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Fibulin-2”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "Fibulin-2"
Sicot, Francois-Xavier, Takeshi Tsuda, Dessislava Markova, John F. Klement, Machiko Arita, Rui-Zhu Zhang, Te-Cheng Pan, Robert P. Mecham, David E. Birk i Mon-Li Chu. "Fibulin-2 Is Dispensable for Mouse Development and Elastic Fiber Formation". Molecular and Cellular Biology 28, nr 3 (10.12.2007): 1061–67. http://dx.doi.org/10.1128/mcb.01876-07.
Pełny tekst źródłaSasaki, T., H. Wiedemann, M. Matzner, M. L. Chu i R. Timpl. "Expression of fibulin-2 by fibroblasts and deposition with fibronectin into a fibrillar matrix". Journal of Cell Science 109, nr 12 (1.12.1996): 2895–904. http://dx.doi.org/10.1242/jcs.109.12.2895.
Pełny tekst źródłaPan, T. C., T. Sasaki, R. Z. Zhang, R. Fässler, R. Timpl i M. L. Chu. "Structure and expression of fibulin-2, a novel extracellular matrix protein with multiple EGF-like repeats and consensus motifs for calcium binding." Journal of Cell Biology 123, nr 5 (1.12.1993): 1269–77. http://dx.doi.org/10.1083/jcb.123.5.1269.
Pełny tekst źródłaSofela, Agbolahan A., David A. Hilton, Sylwia Ammoun, Daniele Baiz, Claire L. Adams, Emanuela Ercolano, Michael D. Jenkinson i in. "Fibulin-2: A Novel Biomarker for Differentiating Grade II from Grade I Meningiomas". International Journal of Molecular Sciences 22, nr 2 (8.01.2021): 560. http://dx.doi.org/10.3390/ijms22020560.
Pełny tekst źródłaSofela, Agbolahan A., David A. Hilton, Sylwia Ammoun, Daniele Baiz, Claire L. Adams, Emanuela Ercolano, Michael D. Jenkinson i in. "Fibulin-2: A Novel Biomarker for Differentiating Grade II from Grade I Meningiomas". International Journal of Molecular Sciences 22, nr 2 (8.01.2021): 560. http://dx.doi.org/10.3390/ijms22020560.
Pełny tekst źródłaKlingen, Tor A., Ying Chen, Hans Aas, Elisabeth Wik i Lars A. Akslen. "Fibulin-2 expression associates with vascular invasion and patient survival in breast cancer". PLOS ONE 16, nr 4 (9.04.2021): e0249767. http://dx.doi.org/10.1371/journal.pone.0249767.
Pełny tekst źródłaCangemi, Claudia, Vibe Skov, Michael Kjaer Poulsen, Jonas Funder, Waleed O. Twal, Mari-Anne Gall, Vibeke Hjortdal i in. "Fibulin-1 Is a Marker for Arterial Extracellular Matrix Alterations in Type 2 Diabetes". Clinical Chemistry 57, nr 11 (1.11.2011): 1556–65. http://dx.doi.org/10.1373/clinchem.2011.162966.
Pełny tekst źródłaCASTOLDI, Mirco, i Mon-Li CHU. "Structural and functional characterization of the human and mouse fibulin-1 gene promoters: role of Sp1 and Sp3". Biochemical Journal 362, nr 1 (8.02.2002): 41–50. http://dx.doi.org/10.1042/bj3620041.
Pełny tekst źródłaZhang, Hong-Yan, Rupert Timpl, Takako Sasaki, Mon-Li Chu i Peter Ekblom. "Fibulin-1 and fibulin-2 expression during organogenesis in the developing mouse embryo". Developmental Dynamics 205, nr 3 (marzec 1996): 348–64. http://dx.doi.org/10.1002/(sici)1097-0177(199603)205:3<348::aid-aja13>3.0.co;2-0.
Pełny tekst źródłaZhang, Hangxiang, Jing Wu, Hailong Dong, Shaukat A. Khan, Mon-Li Chu i Takeshi Tsuda. "Fibulin-2 deficiency attenuates angiotensin II-induced cardiac hypertrophy by reducing transforming growth factor-β signalling". Clinical Science 126, nr 4 (14.10.2013): 275–88. http://dx.doi.org/10.1042/cs20120636.
Pełny tekst źródłaRozprawy doktorskie na temat "Fibulin-2"
Shuen, Wai-ho, i 孫偉豪. "Mechanistic studies of fibulin-2 and its related signaling pathways in nasopharyngeal carcinoma". Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2014. http://hdl.handle.net/10722/206469.
Pełny tekst źródłapublished_or_final_version
Clinical Oncology
Doctoral
Doctor of Philosophy
de, Bock Charles Edo St George Clinical School UNSW. "Novel protein interactors of urokinase-type plasminogen activator receptor". Awarded by:University of New South Wales. St George Clinical School, 2005. http://handle.unsw.edu.au/1959.4/23009.
Pełny tekst źródłaHoriguchi, Masahito. "Latent TGF-β-binding protein 2 binds to DANCE/fibulin-5 and regulates elastic fiber assembly". Kyoto University, 2008. http://hdl.handle.net/2433/135796.
Pełny tekst źródłaSerra, Encinas Noemí. "Estudi genètic d’associació de fibulines i hipertensió arterial i regulació farmacològica de la seva expressió". Doctoral thesis, Universitat Rovira i Virgili, 2016. http://hdl.handle.net/10803/351954.
Pełny tekst źródłaLa composición y estructura de la matriz extracelular en la pared vascular i en las placas arterioscleróticas, son factores muy importantes que determinan la rigidez vascular i la estabilidad de la placa. Por otro lado, la rigidez arterial es un factor clave para la hipertensión arterial. Se ha descrito que las fibulinas -1,-2,-4 y -5 son proteínas estructurales de la matriz extracelular involucradas en diferentes enfermedades cardiovasculares. Por estos motivos, hemos diseñado un estudio genético para valorar la asociación de varios SNPs de las fibulinas -1,-2 y -5 con la hipertensión arterial(HTA) y un estudio in vitro para evaluar los efectos de fármacos utilizados en la prevención cardiovascular sobre la expresión génica y proteica de las fibulinas -1,-2,-4 y -5. Hemos demostrado que variaciones en el gen de la FBLN2(rs3732666 i rs10061376) están asociadas a menor presión arterial sistólica y menos riesgo de padecer HTA i que el rs3732666 también se asocia en diferentes niveles con un menor grosor de la íntima-media carotídeo. Además, en el segundo estudio hemos descrito que en células musculares lisas humanas, 24h de tratamiento con simvastatina aumenta la expresión de fibulina-2 intracelular y secretada tanto a nivel génico como proteico. Además hemos demostrado que el mecanismo involucrado es la inhibición de la via RhoA/ROCK. Estos resultados son la primera evidencia de que el gen de la FBLN2 se asocia con la HTA y que la expresión de fibulina-2 esta regulada por fármacos utilizados como terapia preventiva cardiovascular. De esta manera, el efecto de la simvastatina sobre la expresión de fibulina-2 se podría incluir a la larga lista de efectos pleiotrópicos de las estatinas.
The composition and structure of the extracellular matrix in the vascular wall and atherosclerotic plaque are important factors that determine vascular stiffnes and plaque stability . Furthermore, arterial stiffness is a key factor for hypertension. Described the fibulins -1,-2,-4 and-5 are structural proteins of the extracellular matrix involved in several cardiovascular diseases. So we designed a study to assess the genetic association of multiple SNPs of fibulins -1, -2 and -5 with high blood pressure and an in vitro study to evaluate the effects of drugs used in cardiovascular prevention on gene and protein expression of fibulins -1, -2 , -4. We have shown that variations in the gene FBLN2 ( rs3732666 and rs10061376 ) are associated with lower systolic blood pressure and lower risk of hypertension and also that rs3732666 is associated to varying degrees with a lower intima-media thickness of the carotid . In addition, in the second study described that simvastatin increases gene and protein expression of fibulin-2 at 24 hours of treatment in human smooth muscle cells. Also we demonstrated that the mechanism involved is via inhibition of RhoA / ROCK . These results are the first evidence that gene FBLN2 is associated with hypertension and fibulina -2 expression is regulated by drugs used as preventive cardiovascular. Thus, the effect of simvastatin on the expression of fibulina- 2 could be added to the long list of pleiotropic effects of statins .
Pless, Elin. "Investigation of interactions with extracellular matrix proteins mediated by the CCP modules of the metabotropic GABAB receptor". Thesis, University of Edinburgh, 2010. http://hdl.handle.net/1842/5714.
Pełny tekst źródłaPapon, Marie-Amélie. "Régulation des sous-types d’hétérodimères du récepteur GABAB dans la moelle épinière en conditions de douleurs neuropathiques : rôle des protéines partenaires". Thesis, Bordeaux 2, 2009. http://www.theses.fr/2009BOR21671/document.
Pełny tekst źródłaIn the central nervous system, the inhibitory GABAB receptor is an obligate heterodimeric GPCR that requires the association between GABAB1 (B1a or B1b) and GABAB2 subunits. The heterodimeric GABAB receptor activation has a well-known antinociceptive action in acute pain but its effect appears limited in pathological states. Our hypothesis is that the GABAB activation and signaling could be altered by partner proteins, thus resulting in desinhibition processes in the spinal cord. In the present study, we investigated the role of two partner proteins overexpressed in neuropathic states which decrease GABAB activation through two different mechanisms. On the one hand, the cytosolic 14-3-3? protein induces the dissociation of the heterodimer B1b/B2. This effect occurs in post-synaptic compartments. On the other hand, fibulin-2, an extracellular matrix protein, which decreases the activation of the heterodimer B1a/B2 localized preferentially in presynaptic compartments. Anti-sens strategies (anti-14-3-3? or anti-fibulin-2 siRNA) or competing peptides specific of 14-3-3?/B1b interaction, potentiate the antinociceptive effects of GABAB agonist in an animal model of neuropathic pain. Taken together, our data suggest that GPCR oligomeric state can be modulated in vivo by endogenous partners proteins that are involved in the development and the maintenance of pain sensitization
Części książek na temat "Fibulin-2"
Tsuda, Takeshi, i Mon-Li Chu. "Biological Role of Fibulin-2 in Cardiovascular Development". W Cardiovascular Development and Congenital Malformations, 20–23. Malden, Massachusetts, USA: Blackwell Publishing Ltd, 2007. http://dx.doi.org/10.1002/9780470988664.ch6.
Pełny tekst źródłaIkelle, Larissa, Muna I. Naash i Muayyad R. Al-Ubaidi. "Role of Fibulins 2 and 5 in Retinal Development and Maintenance". W Retinal Degenerative Diseases, 275–80. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-75402-4_33.
Pełny tekst źródłaAmano, Satoshi. "Fibulin-5 Deposition in Human Skin: Decrease with Aging and UVB Exposure and Increase in Solar Elastosis". W Textbook of Aging Skin, 1–9. Berlin, Heidelberg: Springer Berlin Heidelberg, 2015. http://dx.doi.org/10.1007/978-3-642-27814-3_32-2.
Pełny tekst źródłaAyad, Shirley, Ray Boot-Handford, Martin J. Humphries, Karl E. Kadler i Adrian Shuttleworth. "Fibulin-2". W The Extracellular Matrix FactsBook, 156–57. Elsevier, 1998. http://dx.doi.org/10.1016/b978-012068911-8.50135-4.
Pełny tekst źródłaAyad, Shirley, Ray Boot-Handford, Martin J. Humphries, Karl E. Kadler i Adrian Shuttleworth. "Fibulin-1 fibulin, BM-90". W The Extracellular Matrix FactsBook, 153–55. Elsevier, 1998. http://dx.doi.org/10.1016/b978-012068911-8.50134-2.
Pełny tekst źródłaStreszczenia konferencji na temat "Fibulin-2"
Speelman, L., E. Moltzer, K. van der Heiden, P. van Heijningen, A. F. W. van der Steen, J. Essers, F. Gijsen i J. Wentzel. "Biomechanical Characteristics of Aortic Aneurysms Generated in Fibulin-4 Deficient Mice". W ASME 2012 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2012. http://dx.doi.org/10.1115/sbc2012-80590.
Pełny tekst źródłaWan, William, Hiromi Yanagisawa i Rudolph L. Gleason. "Biomechanical and Microstructural Properties of Fibulin-5 Null Mice". W ASME 2009 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2009. http://dx.doi.org/10.1115/sbc2009-206435.
Pełny tekst źródłaLe, Victoria, Hiromi Yanagisawa i Jessica Wagenseil. "Characterization of Cardiac Function and Arterial Mechanics During Early Postnatal Development in Fibulin-5 Null Mice". W ASME 2013 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2013. http://dx.doi.org/10.1115/sbc2013-14282.
Pełny tekst źródłaEspinosa, Gabriela, Lisa Bennett, William Gardner i Jessica Wagenseil. "The Effects of Extracellular Matrix Protein Insufficiency and Treatment on the Stiffness of Arterial Smooth Muscle Cells". W ASME 2013 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2013. http://dx.doi.org/10.1115/sbc2013-14131.
Pełny tekst źródłaShuen, Wai Ho, i Maria Li Lung. "Abstract 4309: Fibulin-2 suppresses tumor growth and angiogenesis through the inhibition of Erk1/2 and p65 pathways in nasopharyngeal carcinoma." W Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-4309.
Pełny tekst źródłaWan, William, i Rudolph L. Gleason. "Collagen Fiber Angle Quantification of Carotid Arteries From Fibulin-5 Null Mice". W ASME 2011 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2011. http://dx.doi.org/10.1115/sbc2011-53685.
Pełny tekst źródłaMoore, John J., Robert M. Moore, Deepak Kumar, Joseph M. Mansour, Brian M. Mercer, Elizabeth Yohannes, Jillian Novak i Mark Chance. "Differential Expression of Fibulin Family Proteins in Mechanically Strong vs. Weak Fetal Membrane Fragments". W ASME 2007 Summer Bioengineering Conference. American Society of Mechanical Engineers, 2007. http://dx.doi.org/10.1115/sbc2007-175332.
Pełny tekst źródłaUnteregger, Gerhard, Volker Jung, Carolin Hach, Joern Kamradt, Matthias Saar i Michael Stoeckle. "Abstract 2351: Down-regulation of Fibulin-5 in invasive growing primary prostate cancer cells". W Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-2351.
Pełny tekst źródłaHu, Bin, Paula A. Agudelo, Joshua C. Saldivar, Hosung Sim, Claire E. Dolan, Maria E. Mora, Gerard J. Nuovo, Susan E. Cole i Mariano S. Viapiano. "Abstract 2353: Fibulin-3, an extracellular matrix protein, regulates Notch signaling and promotes brain tumor cell invasion and survival". W Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-2353.
Pełny tekst źródła